Analysis by Age and Sex of Efficacy Data From Placebo-Controlled Trials of Desvenlafaxine in Outpatients With Major Depressive Disorder

May 18, 2010Journal of clinical psychopharmacology

How age and sex relate to desvenlafaxine's effectiveness in outpatients with major depression

AI simplified

Circadian Biology on OpenScience ↗PubMed ↗DOI ↗

Abstract

Desvenlafaxine resulted in a statistically significant reduction in depression scores compared to placebo, with a change of -1.72 for women and -2.11 for men.

The response rates for desvenlafaxine were 53% for women and 53% for men, compared to 42% and 41% for placebo, respectively.
Remission rates were 31% for women and 34% for men receiving desvenlafaxine, compared to 21% and 26% for placebo.
Significant improvements in depressive symptoms were observed in women aged 18 to 40, 41 to 54, and 65 years and older, and in men aged 18 to 40 and 41 to 54.
No significant interactions were found based on sex or age regarding treatment efficacy.
Overall, desvenlafaxine improved depressive symptoms across different age and sex groups.

AI simplified

This pooled analysis evaluated the efficacy of desvenlafaxine (administered as desvenlafaxine succinate) for the treatment of major depressive disorder (MDD) in patients grouped by age and sex. Nine clinical trials were pooled. Outpatients 18 years or older with MDD received desvenlafaxine 50, 100, 200, or 400 mg/d (men = 709; women = 1096) or placebo (men = 399; women = 709) for 8 weeks. Data were analyzed by sex and by age groups of 40 years and younger, 41 to 54 years, 55 to 64 years, and 65 years and older. The primary outcome was change from baseline in the 17-item Hamilton Rating Scale for Depression (HAM-D17) total score at the final evaluation. Secondary measures included response (> or =50% reduction in HAM-D17) and remission (HAM-D17 < or =7). No significant sex-treatment, age-treatment, or sex-age-treatment interactions were observed. Differences in the HAM-D17 change from baseline for desvenlafaxine versus placebo were -1.72 for women (P < 0.001) and -2.11 for men (P < 0.001); these changes were significant among women of the 18-to-40 (P = 0.01), 41-to-54 (P = 0.002), and 65-years-and-older subgroups (P = 0.02), and significant among men for the 18-to-40 (P = 0.03) and 41-to-54 subgroups (P = 0.002). The response rates for desvenlafaxine and placebo were 53% and 42% (P < 0.001), respectively, among women, and 53% and 41% (P < 0.001), respectively, among men; the remission rates were 31% and 21% (P < 0.001) and 34% and 26% (P = 0.007), respectively. The response rates were similar across age subgroups, with significant differences from placebo observed in the 18-to-40 (P < or = 0.05), 41-to-54 (P < or = 0.005), and 65-and-older subgroups (P = 0.02). The remission rates were significant versus placebo in the 41-to-54 (P = 0.006), 55-to-64 (P = 0.01), and 65-and-older (P = 0.02) subgroups among women but not in any age subgroup among men. Desvenlafaxine generally improved depressive symptoms across age and sex subgroups.

Full Text

Full text is available at the source.

View full text ↗

Analysis by Age and Sex of Efficacy Data From Placebo-Controlled Trials of Desvenlafaxine in Outpatients With Major Depressive Disorder

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the circadian biology brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the circadian biology brief